FINOSE is a bottom up collaboration initiative from the Finnish, Norwegian and Swedish HTA authorities. The framework for the collaboration is laid out in the Memorandum of Understanding, signed by the three Director Generals. The aim is to co-operate on assessment of both relative efficacy and applicable parts of a health economic analysis.

Based on the collaborative assessment, each partner will individually make a national decision, in accordance with their national regulations.

In practice, participating in the collaboration normally means simultaneous submissions to the three countries, and signing a waiver on data sharing. In case of an ongoing European level (EUnetHTA) assessment, we are interested in exploring the possibilities for building the economic evaluation on the results of the EUnetHTA assessment.

Within the FINOSE collaboration we wish to:
- Support timely and equal access to medical technologies
- Gain additional knowledge about the products
- Increase efficiency in production of assessment reports
- Have less divergence in HTA methodologies and evidence requirements
- Have reduced complexity in industry submissions
- Contribute to a system that is beneficial both for the collaborating authorities and the pharmaceutical company

FINOSE achievements so far:
- We have dialogues with stakeholders as decision makers and interested companies
- Methodology workshops
- Awaiting two FINOSE applications this year

We see a future for joint development of HTA in a rapidly progressing pharmaceutical environment. The pilot collaboration was launched in March 2018 and will end in 2020.